Gastroesophageal Reflux Disease (GERD)

Oncology·MeSH: Gastroesophageal Reflux

Prevalence

10903.8 / 100K

Incidence

4267.4 / 100K/yr

10 drugs in development·9 companies·1 clinical trial

Drug Pipeline by Phase

Approved(10)

Drug	Company
dexlansoprazole	Mylan II B.V. (MYL)
famotidine	ENGENE HOLDINGS INC. (ENGN)
famotidine	Avita Medical Inc. (RCEL)
famotidine	Mersana Therapeutics, Inc. (MRSN)
famotidine	SUNSET ISLAND GROUP (SUN)
famotidine	Seagen Inc. (SGEN)
famotidine	Miromatrix Medical Inc. (MIRO)
inFoods® (IBS)	BIOMERICA INC (BMRA)
pantoprazole	EXELIXIS, INC. (EXEL)
pantoprazole	SUNSET ISLAND GROUP (SUN)

BioSniper tracks 10 drugs in development for Gastroesophageal Reflux Disease (GERD) across 9 companies.

There are 1 clinical trial targeting Gastroesophageal Reflux Disease (GERD) tracked by BioSniper.

The estimated prevalence of Gastroesophageal Reflux Disease (GERD) is approximately 10903.8 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.